Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk of Treatment Failure and Death after Ablation in Hepatocellular Carcinoma Patients-A Multiparametric Prediction.
Muñoz-Martínez S, Sapena V, García-Criado Á, Darnell A, Forner A, Belmonte E, Sanduzzi-Zamparelli M, Rimola J, Soler A, Llarch N, Iserte G, Mauro E, Ayuso C, Rios J, Bruix J, Vilana R, Reig M. Muñoz-Martínez S, et al. Among authors: iserte g. Cancers (Basel). 2023 Jun 21;15(13):3269. doi: 10.3390/cancers15133269. Cancers (Basel). 2023. PMID: 37444380 Free PMC article.
Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules.
Sanduzzi-Zamparelli M, Mariño Z, Lens S, Sapena V, Iserte G, Pla A, Granel N, Bartres C, Llarch N, Vilana R, Nuñez I, Darnell A, Belmonte E, García-Criado A, Díaz A, Muñoz-Martinez S, Ayuso C, Bianchi L, Fuster-Anglada C, Rimola J, Forner A, Torres F, Bruix J, Forns X, Reig M. Sanduzzi-Zamparelli M, et al. Among authors: iserte g. J Hepatol. 2022 Apr;76(4):874-882. doi: 10.1016/j.jhep.2021.11.023. Epub 2021 Nov 29. J Hepatol. 2022. PMID: 34856322
Current pharmacological treatment of hepatocellular carcinoma.
Muñoz-Martínez S, Iserte G, Sanduzzi-Zamparelli M, Llarch N, Reig M. Muñoz-Martínez S, et al. Among authors: iserte g. Curr Opin Pharmacol. 2021 Oct;60:141-148. doi: 10.1016/j.coph.2021.07.009. Epub 2021 Aug 19. Curr Opin Pharmacol. 2021. PMID: 34418875 Free article. Review.
Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs.
Díaz-González Á, Sapena V, Boix L, Torres F, Sanduzzi-Zamparelli M, Da Fonseca LG, LLarch N, Iserte G, Guedes C, Muñoz-Martínez S, Darnell A, Belmonte E, Rimola J, Forner A, Ayuso C, Bruix J, Reig M. Díaz-González Á, et al. Among authors: iserte g. United European Gastroenterol J. 2021 Jul;9(6):655-661. doi: 10.1002/ueg2.12111. Epub 2021 Jul 6. United European Gastroenterol J. 2021. PMID: 34228394 Free PMC article.
Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma.
Corominas J, Sapena V, Sanduzzi-Zamparelli M, Millán C, Samper E, Llarch N, Iserte G, Torres F, Da Fonseca LG, Muñoz-Martínez S, Forner A, Bruix J, Boix L, Reig M. Corominas J, et al. Among authors: iserte g. Cancers (Basel). 2021 Jan 23;13(3):426. doi: 10.3390/cancers13030426. Cancers (Basel). 2021. PMID: 33498698 Free PMC article.
Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials.
Díaz-González Á, Sapena V, Boix L, Brunet M, Torres F, LLarch N, Samper E, Millán O, Corominas J, Iserte G, Sanduzzi-Zamparelli M, da Fonseca LG, Darnell A, Belmonte E, Forner A, Ayuso C, Bruix J, Reig M. Díaz-González Á, et al. Among authors: iserte g. Liver Int. 2020 Oct;40(10):2476-2488. doi: 10.1111/liv.14587. Epub 2020 Jul 25. Liver Int. 2020. PMID: 33021346
12 results